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Sir
Iacopetta et al draw attention to a very important question: which
patients will beneﬁt the most from adjuvant therapy in colorectal
cancer (Maughan, 2001). Earlier, they reported on a retrospective,
non-randomised study of surgery with or without 5FU and Leva-
misole among 656 patients in Western-Australia, a treatment
interaction with gender, localisation of the tumour and microsatel-
lite instability (MSI) (Elsaleh et al, 2000). By extending their series,
up to 891 stage III colorectal cancer patients, similar results were
found with p53 in addition (Elsaleh et al, 2001). Chemotherapy
provided maximal beneﬁt in female patients and p53 normal
tumours.
In the Dutch NACCP trial a beneﬁcial effect of adjuvant treatment
was found in stage II and III (Taal et al, 2001). However, as the
NACCP trial was stopped early we did not reach enough statistical
power to perform reliable subgroup analysis. Female patients seemed
to beneﬁt more than male, but conﬁdence intervals were wide and the
result was not statistically signiﬁcant. Likewise adjuvant therapy
appeared not to be of beneﬁt in rectal cancer, but again, no signiﬁcant
interaction of treatment and tumour site was found and further
exploration is warranted.
Like others (Watanabe et al, 2001) we have explored the role
of molecular markers to select patients who might beneﬁt most
from adjuvant treatment. In a random sample of 116 patients
(64 male, 53 female) in either stage II (n=57) or stage III
(n=59), colonic cancer (n=82) as well as rectal cancer (n=34)
in fourteen patients (12%) MSI was found and in 43 cases
LOH chr18 (37%). MSI was almost exclusively found in colon
cancer (n=13) and only once in rectal cancer, whereas LOH
chr18 was present in two-thirds of colon cancer (n=28), but also
in rectal cancer patients (n=15). Difference in gender and stage
were not apparent. Disease speciﬁc survival revealed a superb
result for the MSI positive group (100% at 5 years); in the
LOH chr18 group survival was worse, but clearly better than
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Years from registration
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no RER/LOH      59          18
RER+                 14             0
LOH chr.18         43          16
LOH chr.18        43              41              39              35              26              19
RER+                 14              13              12              11              10                9
no RER/LOH     59                52              47              42              35              34 
Figure 1 *Correspondence: BG Taal; E-mail: b.taal@nki.nl
Letters to the Editor
1525
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1524–1526in the group without molecular markers (Figure 1). Subdividing
the groups according to treatment makes no sense due to the
small number of patients.
In conclusion, our preliminary data of molecular markers do
show a major potential role for MSI instability as prognostic
marker, but await inclusion of more patients.
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